Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate.
Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in mprF, resulting in a T345A substitution, associated with non-susceptibility to daptomycin.
Murthy
Madhukiran H
MH
Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA.
Olson
Michael E
ME
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
Wickert
Robert W
RW
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
Fey
Paul D
PD
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
Jalali
Ziba
Z
Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA.
D000328:Adult; D000900:Anti-Bacterial Agents; D017576:Daptomycin / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D015819:Substance Abuse, Intravenous / Q000150:complications
D000900:Anti-Bacterial Agents; D017576:Daptomycin